Gouji Toyokawa

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Brain Metastases

Acute Lymphoblastic Leukemia

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Airi Fujimoto, Gouji Toyokawa, Yoshimichi Koutake, Shigeru Kimura, Yosei Kawamata, Kazuhisa Fukuishi, Koji Yamazaki, Sadanori Takeo
Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thoracic cancer 12 (15) (2021)
Keisuke Yamamoto, Gouji Toyokawa, Yuka Kozuma, Fumihiro Shoji, Koji Yamazaki, Sadanori Takeo
ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report. Thoracic cancer 12 (11) (2021)
Nobuhisa Ando, Kentaro Tanaka, Kohei Otsubo, Gouji Toyokawa, Yuki Ikematsu, Maako Ide, Yasuto Yoneshima, Eiji Iwama, Hiroyuki Inoue, Kayo Ijichi, Tetsuzo Tagawa, Yoichi Nakanishi, Isamu Okamoto
Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. Thoracic cancer 11 (10) (2020)
Naoki Haratake, Takashi Seto, Shinkichi Takamori, Ryo Toyozawa, Kaname Nosaki, Naoko Miura, Taro Ohba, Gouji Toyokawa, Kenichi Taguchi, Masafumi Yamaguchi, Mototsugu Shimokawa, Mitsuhiro Takenoyama
Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thoracic cancer 10 (9) (2019)
Gouji Toyokawa, Yuichi Yamada, Tetsuzo Tagawa, Yoshinao Oda
Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection. Thoracic cancer 9 (10) (2018)